HighTower Advisors
CRBU icon

HighTower Advisors’s Caribou Biosciences CRBU Stock Holding History

HighTower Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.2K Hold
16,934
– – ﹤0.01% 3739
2025
Q4 		$26.9K Hold
16,934
– – ﹤0.01% 3602
2025
Q3 		$39.5K Sell
16,934
-200
-1% -$378 ﹤0.01% 3625
2025
Q2 		$21.6K Buy
17,134
+3,917
+30% +$3.85K ﹤0.01% 3612
2025
Q1 		$12.1K Buy
13,217
+296
+2% +$385 ﹤0.01% 3550
2024
Q4 		$20.5K Buy
+12,921
New +$26K ﹤0.01% 3541

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors's CRBU Position: Q1 2026 in Review

HighTower Advisors held its Caribou Biosciences (CRBU) position steady in Q1 2026 at 16,934 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

HighTower Advisors first reported a position in CRBU in Q4 2024 and has held it in 6 quarters since. The position peaked at $39.5K in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • HighTower Advisors held 16,934 shares of Caribou Biosciences worth $32.2K as of Q1 2026.
  • HighTower Advisors left its Caribou Biosciences share count unchanged in Q1 2026.
  • Caribou Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3739 holding.
  • HighTower Advisors first reported a position in Caribou Biosciences in Q4 2024 and has held it in 6 quarters since.
  • HighTower Advisors's Caribou Biosciences position peaked at $39.5K in Q3 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.